Pay in 4 interest-free payments of $5.97 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Indications: Type 2 diabetes, CV risk reduction in T2D patients with heart disease Doses: 0.6 mg (starter) 1.2 mg 1.8 mg/day Best for: Patients wanting a daily injectable with strong CV data Rybelsus (Oral Semaglutide Tablet) Rybelsus is the only oral GLP-1 medication currently available
GLP-1 signals fullness, prompts insulin from the pancreas, and slows stomach emptying
Off-label Administration Intranasal administration (compounded): Due to patient preference for non-injectable options, compounding pharmacies frequently formulate PT-141 as intranasal sprays
Common subcutaneous sites include: Abdomen: In order to minimize pain and maximize absorption, this site is recommended only for volumes less than or equal to 0.3 mL
What Is Liposomal Encapsulation Technology
